§ 63-1-401. Part Definitions — Development of Recommended Treatment Guidelines for Prescribing Opioids — Development of Pain Clinic Guidelines — Study of Co-Prescription of Naloxone With Opioid — Review of Guidelines — Notification of Licensees

As used in this part: “Commissioner” means the commissioner of health; “Pain clinic guidelines” means systematically developed standards to assist healthcare providers and pain clinic certificate holders in making decisions concerning the appropriate medical care for chronic nonmalignant pain treatment, as defined in § 63-1-301; and “Treatment guidelines” means systematically developed statements to assist healthcare […]

§ 63-1-402. Prescribers Required to Hold a Current Federal Dea License and to Complete Continuing Education — Exceptions to Application of Part

On or after July 1, 2014, all prescribers who hold a current federal drug enforcement administration (DEA) license and who prescribe controlled substances shall be required to complete a minimum of two (2) hours of continuing education related to controlled substance prescribing biennially to count toward the licensees’ mandatory continuing education. The continuing education must […]

§ 63-1-403. Nonresidential Buprenorphine Treatment Guidelines

As used in this section: “Commissioners” means the commissioner of mental health and substance abuse services and the commissioner of health; and “Nonresidential buprenorphine treatment guidelines” means systematically developed standards to assist any practitioners authorized by the state to prescribe buprenorphine-containing products for the treatment of opioid use disorder as defined in the latest version […]